Factors that may influence the risk of cancer in diabetes

Farmacia

Volumn 60, Issue 5, 2012, Pages 602-614

  Miulescu, Rucsandra Dǎnciulescu ^a   Dǎnoiu, Suzana ^b   Purcǎrea, Victor ^a   Ionescu Tîrgovişe, Constantin ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Cancer; Diabetes mellitus; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID; INCRETIN; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; CHRONIC DISEASE; COLON CANCER; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG SAFETY; ENDOMETRIUM CANCER; HUMAN; HYPERGLYCEMIA; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; METABOLIC REGULATION; MITOGENICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS CANCER; PHYSICAL ACTIVITY; PROSTATE CANCER; QUALITATIVE ANALYSIS; RECTUM CANCER; SEX DIFFERENCE; SMOKING; THYROID CARCINOMA;

EID: 84867498946     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Kuriyama S, Tsubono Y, Hozawa A, Shimazu T, Suzuki Y, Koizumi Y, Ohmori K, Nishino Y, Tsuji I. Obesity and risk of cancer in Japan. Int J Cancer 113: 148-157, 2005.
2. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A metaanalysis of prospective studies. Int J Cancer 120: 1993-1998, 2007.
3. Larsson SC, Wolk A. Epidemiology of obesity and diabetes: prevalence and trends. In Obesity and Diabetes, Mantzoros C (ed) pp 15-36. Boston: Humana Press, 2006.
4. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer 96: 1457-1461, 2007.
5. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R: Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123, 2009.
6. Edward Giovannucci, David M. Harlan, Michael C. Archer, Richard M. Bergenstal, Susan M. Gapstur, Laurel A. Habel, Michael Pollak, Judith G. Regensteiner, Douglas Yee. Diabetes and Cancer: A Consensus Report, Diabetes Care, 33:1674-85, 2010.
7. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts & Figures 2007. Atlanta, Georgia, American Cancer Society, 2007.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
9. Harris MI, Flegal KM. Cowie C C, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. Diabetes Care, 21:518-524, 1998.
10. American Cancer Society. ACS report calls for greater cancer prevention efforts. Retrieved July1,2010, from http://www.cancer.org/Cancer/news/acs-report-calls-for-greater-prevention-efforts2010.
11. Obesity Society.(n.d.). Cancer and obesity, 2010, http://www.obesity.org/information/cancer_obesity.asp, 2010.
12. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 58 (4): 773-81, 2006.
13. Yaghmaie F, Saeed O, Garan SA, Freitag W, Timiras PS, Sternberg H. Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice. Neuro Endocrinol. Lett. 26 (3): 197-203, 2005.
14. Hess, RA. Estrogen in the adult male reproductive tract: a review. Reproductive Biology and Endocrinology 1 (52): 52, 2003.
15. Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc. Res. 53 (3): 709-19, 2005.
16. Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116 (3): 561-7, 2006.
17. Cohen S. M., Ellwein L. B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res, 51: 6493-6505, 1991.
18. Preston-Martin S., Pike M. C., Ross R. K., Jones P. A., Henderson B. E. Increased cell division as a cause of human cancer. Cancer Res, 50: 7415-7421, 1990.
19. Cory S., Vaux D. L., Strasser A., Harris A. W., Adams J. M. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res, 59: 1685s-1692s, 1999.
20. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8: 915-928, 2008.
21. Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, Roberts CT Jr. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol, 27: 3569-3577, 2007.
22. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab, 17: 328-336, 2006.
23. Rechler M. M. Insulin-like growth factor binding proteins. Vitam. Horm, 47: 1-114, 1993.
24. Lee P. D., Giudice L. C., Conover C. A., Powell D. R. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med, 216: 319-357, 1997.
25. Franks S., Kiddy D. S., Hamilton-Fairley D., Bush A., Sharp P. S., Reed M. J. The role of nutrition and insulin in the regulation of sex hormone binding globulin. J. Steroid Biochem. Mol. Biol, 39: 835-838, 1991.
26. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol, 115:911-9, 2005.
27. +/+ colonic epithelial cell lines. Cancer Epidemiol Biomarkers Prev, 14: 1646-52, 2005.
28. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A, 101: 2476-81 2004.
29. Bajou K. Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis]. Bull Mem Acad Roy Med Belg 157: 313-318, 2002.
30. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23: 6986-6990, 2004.
31. Hou Wk, Xu YX, Yu T, Zhang L, et al. Adipocytokines and breast cancer risk. Chin Med J, 120:1592-6, 2007.
32. Ionicǎ FE, Pisoschi C, Negreş S, Nikos RF, Tǎrâţǎ M, Popescu F, Atorvastatin influence on glycemic control in patients with type 2 diabetes mellitus., Farmacia, 2010, 58(6), 728-734
33. Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano et al. Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Science, 101:1286-1291, 2010.
34. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-α as a tumour promoter. Eur J Cancer 42: 745-50, 2006.
35. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 12 (1): 33-40, 2001.
36. Engeset Dagrun, Dyachenko Alina, Ciampi Antonio, Lund Eiliv. Dietary patterns and risk of cancer of various sites in the Norwegian European Prospective Investigation into Cancer and Nutrition cohort: the Norwegian Women and Cancer study. European Journal of Cancer Prevention, 18: 69-75, 2009.
37. Lee I, Oguma Y. Physical activity. In: Schottenfeld D, Fraumeni JF, editors. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press, 2006.
38. Paveliu MS, Bengea S, Paveliu FS, Individualized drug response related to genetic variations of cytochrome P450 isoforms and other enzymes, Farmacia, 2010, 58(3), 245-254
39. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
40. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 23:2838-49, 2004.
41. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharm Toxicol.;44:239-267, 2004.
42. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol. 14:259-66, 2004.
43. Totan A, Greabu M, Mitrea N, Mohora M, Arsene AL, Relationships between erythrocyte Na+/K+-Atpase activity, oxidative stress and high blood pressure in hypertensive diabetic patients, Farmacia, 2010, 58(3), 322-331
44. Denisa Marginǎ, Daniela Grǎdinaru, Niculina Mitrea-Development of a potentiometric method for the evaluation of redox status in human serum, Revue Roumaine de Chimie, 54 45-48, 2009.
45. Charlotte M. Boney II, Hiroko Sekimoto, Philip A. Gruppuso and Jr. A. Raymond Frackelton. Src Family Tyrosine Kinases Participate in Insulin-like Growth Factor I Mitogenic Signaling in 3T3-L1 Cells. Cell Growth & Differentiation, 12 379-386, 2001.
46. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer, 107:873-7, 2003.
47. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell, 129:1261-74, 2007.
48. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298:1911-2, 2002.
49. Belfiore A The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des, 13(7):671-86, 2007.
50. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cel, l 1:339-53. 2002.
51. Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene, 26:1636-44, 2007.
52. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets, 12:589-603, 2008.
53. C. Kazda, L. Slieker, L. Ilag, R. Byrd, T. Rees, M. Prince. Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and antiapoptotic activity in cultured cancer cells. Diabetes Metab Res Rev, 26(3): 145-9, 2010.
54. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev, 25:41-49, 2009.
55. Drucker D, Sherman S, Grelick F, Bergenstal R, Sherwin R, Buse J. Terapiile pe baza de incretine in diabetul zaharat tip 2: evaluarea riscurilor si beneficiilor. Diabetes Care., 3(2): 117-123, 2010.
56. Pro B, Dang N. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 19 (4): 1345-51, 2004.
57. Masur K et al. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept. 137 (3): 147-55, 2006.
58. Wesley UV et al. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway Cancer Res. 65 (4): 1325-34, 2005.
59. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/peptidyl peptidase IV in cancer. Front. Biosci. 13: 1634-45, 2008.
60. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab, 86: 2170-2177, 2001.